Trump Media Says Truth API Draws 10+ Customers as Conflict Concerns Grow 
OpenAI Restricts Astra AI Over Cyberattack Risks 
Oil Prices Rise as Hormuz Tensions Threaten Global Supply 
Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss 
Australia Sets New Minimum Pay, Insurance Rules for Gig Workers 
Mercedes-Benz Stock Offers Deep-Value Potential as Citi Sees Recovery Catalysts 
Apple Tests China’s CXMT Memory Chips for iPhones and MacBooks Amid AI Supply Crunch 
CBA Posts Record A$10.98B Profit Despite Cautious Outlook 
U.S. Stock Futures Flat Ahead of July CPI Data 
Trump Weighs Capital Gains Tax Cuts Ahead of Midterms 
Asian Stocks Mixed as RBA Holds Rates, Oil Risks Rise 
Yen Stabilizes After Intervention Slide as Australian Dollar Hits Eight-Week High 
Singapore Raises 2026 GDP Growth Forecast to 4.5%-5.5% as AI Boom Fuels Economy 
European Stocks Flat as Oil Prices Rise, US CPI in Focus 
Nvidia Secures $500 Billion AI Infrastructure Push With Wall Street Giants 
Asian Currencies Steady Ahead of US CPI as Oil Prices Rise 
Asian Stocks Rise as AI Chip Rally Lifts South Korea, Japan 
Pfizer inc., an American pharmaceutical and biotechnology firm headquartered in Manhattan, New York City, has agreed to buy Global Blood Therapeutics biotech company for $5.4 billion. The drugmaker will be paying $68.50 a share for the acquisition.
According to Reuters, Pfizer will purchase the blood disorder medicine producer as it would like to bolster its drug lineup to counter or fight a possible slowdown in the demand for COVID medicines and other products since the cases are starting to fall.
Pfizer was one of the drugmakers that earned the most at the height of the COVID-19 pandemic since it supplied the vaccines around the world. With most people worldwide now fully vaccinated, the company is now looking for acquisitions that will bring in profits annually
Pfizer confirmed on Monday, Aug. 8, that it will be paying $68.50 per share to buy Global Blood Therapeutics. This amount is equivalent to a premium of around 7.3% to the stock's closing price last Friday.
Following the announcement of the deal with Pfizer, the shares of Global Blood reportedly soared by 4.5%. The company is known for its blood disorder drug called Oxbryta, which was first approved in 2019.
It is used for the treatment of sickle cell disease in patients who are 12 years old or older. In December 2021, it was also approved for the treatment of younger patients who are suffering from the said disease.
“Sickle cell disease is the most common inherited blood disorder, and it disproportionately affects people of African descent. We are excited to welcome GBT colleagues into Pfizer and to work together to transform the lives of patients, as we have long sought to address the needs of this underserved community,” Pfizer’s chairman and chief executive officer, Albert Bourla, said in a press release.
He added, “The deep market knowledge and scientific and clinical capabilities we have built over three decades in rare hematology will enable us to accelerate innovation for the sickle cell disease community and bring these treatments to patients as quickly as possible.”
